211 related articles for article (PubMed ID: 33472383)
1. Efficacy of Trimetazidine in Limiting Periprocedural Myocardial Injury in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
Wang C; Chen W; Yu M; Yang P
Angiology; 2021 Jul; 72(6):511-523. PubMed ID: 33472383
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of Nicorandil effectiveness on myocardial protection after percutaneous coronary intervention.
Zhao XT; Zhang CF; Liu QJ
BMC Cardiovasc Disord; 2019 Jun; 19(1):144. PubMed ID: 31200660
[TBL] [Abstract][Full Text] [Related]
3. Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial.
Wu L; Luan Y; Li Y; Wang M; He J; Jin C; Zhang W
BMC Cardiovasc Disord; 2020 Jun; 20(1):273. PubMed ID: 32503494
[TBL] [Abstract][Full Text] [Related]
4. Role of metabolic manipulator trimetazidine in limiting percutaneous coronary intervention-induced myocardial injury.
Kazmi DH; Kapoor A; Sinha A; Ambesh P; Kashyap S; Khanna R; Kumar S; Garg N; Tewari S; Goel PK
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S365-S371. PubMed ID: 30595291
[TBL] [Abstract][Full Text] [Related]
5. Effect of Trimetazidine in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.
Zhang Y; Ma XJ; Shi DZ
PLoS One; 2015; 10(9):e0137775. PubMed ID: 26367001
[TBL] [Abstract][Full Text] [Related]
6. Trimetazidine in the Prevention of Tissue Ischemic Conditions.
Kallistratos MS; Poulimenos LE; Giannitsi S; Tsinivizov P; Manolis AJ
Angiology; 2019 Apr; 70(4):291-298. PubMed ID: 29888611
[TBL] [Abstract][Full Text] [Related]
7. The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI.
Li R; Tang X; Jing Q; Wang Q; Yang M; Han X; Zhao J; Yu X
Am J Emerg Med; 2017 Nov; 35(11):1657-1661. PubMed ID: 28587952
[TBL] [Abstract][Full Text] [Related]
8. Remote ischaemic conditioning for myocardial infarction or elective PCI: systematic review and meta-analyses of randomised trials.
Haller PM; Vargas KG; Haller MC; Piackova E; Wojta J; Gyöngyösi M; Gersh BJ; Kiss A; Podesser BK; Huber K
Eur Heart J Acute Cardiovasc Care; 2020 Mar; 9(1_suppl):82-92. PubMed ID: 29911392
[TBL] [Abstract][Full Text] [Related]
9. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention.
Labrou A; Giannoglou G; Zioutas D; Fragakis N; Katsaris G; Louridas G
Am J Cardiovasc Drugs; 2007; 7(2):143-50. PubMed ID: 17503885
[TBL] [Abstract][Full Text] [Related]
10. Effect of trimetazidine on incidence of major adverse cardiac events in coronary artery disease patients undergoing percutaneous coronary intervention: A protocol for systematic review and meta-analysis.
Zhu K; Zheng YS; Fang Y
Medicine (Baltimore); 2020 Oct; 99(44):e22918. PubMed ID: 33126352
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of preoperative trimetazidine on myocardial preservation in coronary artery bypass graft patients: a systematic review and meta-analysis.
Zhang N; Lei J; Liu Q; Huang W; Xiao H; Lei H
Cardiology; 2015; 131(2):86-96. PubMed ID: 25871315
[TBL] [Abstract][Full Text] [Related]
12. Protection of Ivabradine Combined with Trimetazidine on Myocardial Injury after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease Evaluated by Magnetic Resonance Image under Convolutional Neural Network.
Chen C
Contrast Media Mol Imaging; 2021; 2021():3150938. PubMed ID: 34629991
[TBL] [Abstract][Full Text] [Related]
13. Effect of one-cycle remote ischemic preconditioning to reduce myocardial injury during percutaneous coronary intervention.
Zografos TA; Katritsis GD; Tsiafoutis I; Bourboulis N; Katsivas A; Katritsis DG
Am J Cardiol; 2014 Jun; 113(12):2013-7. PubMed ID: 24793669
[TBL] [Abstract][Full Text] [Related]
14. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Chia S; Senatore F; Raffel OC; Lee H; Wackers FJ; Jang IK
JACC Cardiovasc Interv; 2008 Aug; 1(4):415-23. PubMed ID: 19463339
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.
Woo JS; Kim W; Ha SJ; Kim JB; Kim SJ; Kim WS; Seon HJ; Kim KS
Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2252-60. PubMed ID: 23868944
[TBL] [Abstract][Full Text] [Related]
16. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial.
Crimi G; Pica S; Raineri C; Bramucci E; De Ferrari GM; Klersy C; Ferlini M; Marinoni B; Repetto A; Romeo M; Rosti V; Massa M; Raisaro A; Leonardi S; Rubartelli P; Oltrona Visconti L; Ferrario M
JACC Cardiovasc Interv; 2013 Oct; 6(10):1055-63. PubMed ID: 24156966
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin reduces ischemia-reperfusion injury in patients with acute coronary syndrome treated with percutaneous coronary intervention.
Jiang F; Yang J; Zhang L; Li R; Zhuo L; Sun L; Zhao Q
Clin Cardiol; 2014 Sep; 37(9):530-5. PubMed ID: 25156269
[TBL] [Abstract][Full Text] [Related]
18. The effect of intravenous vitamin C infusion on periprocedural myocardial injury for patients undergoing elective percutaneous coronary intervention.
Wang ZJ; Hu WK; Liu YY; Shi DM; Cheng WJ; Guo YH; Yang Q; Zhao YX; Zhou YJ
Can J Cardiol; 2014 Jan; 30(1):96-101. PubMed ID: 24365194
[TBL] [Abstract][Full Text] [Related]
19. Remote ischemic conditioning during primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: a systematic review and meta-analysis.
Gong R; Wu YQ
J Cardiothorac Surg; 2019 Jan; 14(1):14. PubMed ID: 30696461
[TBL] [Abstract][Full Text] [Related]
20. Intra-coronary morphine versus placebo in the treatment of acute ST-segment elevation myocardial infarction: the MIAMI randomized controlled trial.
Le Corvoisier P; Gallet R; Lesault PF; Audureau E; Paul M; Ternacle J; Ghostine S; Champagne S; Arrouasse R; Bitari D; Mouillet G; Dubois-Randé JL; Berdeaux A; Ghaleh B; Deux JF; Teiger E
BMC Cardiovasc Disord; 2018 Oct; 18(1):193. PubMed ID: 30340532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
